ArticleBritish journal of cancer1990
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.
Article in British journal of cancer, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 75 citations in OpenAlex.
- Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.International journal of gastrointestinal cancer · 2005Trial
- Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Article
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Experimental and molecular pathology · 2009Review
- Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.British journal of cancer · 2008Article
- Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification.The Journal of molecular diagnostics : JMD · 2003Article
- Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.Molecular pathology : MP · 1999Article
- Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.British journal of cancer · 1997Article
- The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.Breast cancer research and treatment · 1995Article
- Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma.British journal of cancer · 1995Article
- The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer.Journal of cancer research and clinical oncology · 1995Article
- Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.Journal of neuro-oncology · 1995Article
- C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.Breast cancer research and treatment · 1994Article
- A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines.The EMBO journal · 1993Article
- Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.Journal of clinical pathology · 1992Article
- Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.Breast cancer research and treatment · 1991Article
- c-erbB-2 expression in different histological types of invasive breast carcinoma.Journal of clinical pathology · 1991Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we have investigated the expression of the proto-oncogene c-erbB2 in a total of 70 human primary breast tumours. In agreement with other workers, we observed c-erbB2 gene amplification in 17.5% of the tumours studied. In addition, we carried out a comprehensive analysis of c-erbB2 mRNA expression in the tumours using RNase mapping and in situ hybridisation techniques. Our results indicated a more frequent (30%) overexpression of c-erbB2 mRNA, which was associated only with breast carcinomas of a ductal origin. Furthermore, analysis of the c-erbB2 mRNA gene locus in the same tumours demonstrated that enhanced c-erbB2 expression could occur in the presence or absence of gene amplification, suggesting that additional molecular mechanisms may result in overexpression of c-erbB2 mRNA in human mammary tumours. In situ hybridisation showed that elevated levels of c-erbB2 mRNA were specific to malignant cells within the breast tumour. Analysis of the association between c-erbB2 mRNA overexpression and clinicopathological factors revealed a significant correlation with poor tumour grade, but not with steroid receptor status or patient menopausal status. No significant correlation was observed between overexpression of c-erbB2 mRNA and early disease recurrence in our group of patients, although there was a definite trend towards poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.